Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Square PharmaceuticalsDHA:SQURPHARMA -0.42%94 Interest Coverage is 237.12 as of Mar. 2026, which is 100% below its 10-year median of 102,594.57. GuruFocus rates DHA:SQURPHARMA with a GF Score™ of 94/100 and a GF Value™ of BDT219.96 (Fairly Valued). The stock has 3 warning signs investors should review. Among 677 Drug Manufacturers companies, Square Pharmaceuticals ranks better than 84.05% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Square Pharmaceuticals's
Operating Income
for the
three
months ended in Mar. 2026 was BDT5,048 Mil. Square Pharmaceuticals's Interest Expense for the
three
months ended in Mar. 2026 was BDT-21 Mil.
Square Pharmaceuticals's interest coverage for the quarter that ended in Mar. 2026 was 237.12.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Square Pharmaceuticals PLC has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Square Pharmaceuticals's Interest Coverage or its related term are showing as below:
DHA:SQURPHARMA'
s Interest Coverage Range Over the Past 10 Years
Min: 74.62 Med: 102594.57 Max: 1178655.31
Current: 183.93
DHA:SQURPHARMA's Interest Coverage is ranked better than 84.05% of 677
companies
in the Drug Manufacturers industry
Industry Median: 12.99
vs DHA:SQURPHARMA: 183.93
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Square Pharmaceuticals Interest Coverage Related Terms
Square Pharmaceuticals Interest Coverage Historical Data
* Premium members only.
The historical data trend for Square Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
DHA:SQURPHARMA vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Square Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Square Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Square Pharmaceuticals (DHA:SQURPHARMA) has a Interest Coverage of 237.12 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Square Pharmaceuticals and its competitors. This is 100% below median its historical median of 102,594.57. Over the past decade, Square Pharmaceuticals' Interest Coverage has ranged from 74.62 to 1,178,655.31. According to the industry distribution chart, Square Pharmaceuticals ranks #108 out of 677 companies in the Drug Manufacturers industry, placing it in the top 16%.
Is Square Pharmaceuticals' Interest Coverage too high?
Square Pharmaceuticals' current Interest Coverage of 237.12 is 100% below median its 10-year median of 102,594.57. Over the past 10 years, this metric has ranged from a low of 74.62 to a high of 1,178,655.31. The Drug Manufacturers industry median Interest Coverage is 12.99. Square Pharmaceuticals' value of 237.12 is 1725.4% above this industry median. Based on the distribution chart, Square Pharmaceuticals ranks #108 out of 677 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Square Pharmaceuticals has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Square Pharmaceuticals' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Square Pharmaceuticals ranks #108 out of 677 companies for Interest Coverage. This places Square Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.99. Square Pharmaceuticals' value of 237.12 is 1725.4% above this benchmark. Historically, Square Pharmaceuticals' own Interest Coverage has ranged from 74.62 to 1,178,655.31 over the past decade. While the company's 10-year median is 102,594.57 vs. the industry median of 12.99, Square Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.99, based on 677 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Square Pharmaceuticals's current Interest Coverage of 237.12 is 1725.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Square Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Square Pharmaceuticals's current Interest Coverage is 237.12, which is 100% below median its own 10-year median of 102,594.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Square Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Square Pharmaceuticals (DHA:SQURPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is BDT219.96, compared to a current price of BDT214.70 — trading 2.4% below its estimated fair value. The current Interest Coverage is 237.12, which is 100% below median its 10-year median of 102,594.57 and 1725.4% above the Drug Manufacturers industry median of 12.99. Square Pharmaceuticals' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Square Pharmaceuticals (DHA:SQURPHARMA), the current Interest Coverage is 237.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Square Pharmaceuticals (DHA:SQURPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Square Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT214.70 is trading 2.4% below its estimated GF Value™ of BDT219.96.
GuruFocus considers Square Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:SQURPHARMA:
Interest Coverage: 237.12 (100% below median its 10-year median of 102,594.57)
GF Value™: BDT219.96 vs. price of BDT214.70 (2.4% below fair value)
Industry Position: 1725.4% above the Drug Manufacturers median (#108 of 677)
No single metric tells the full story. See the DHA:SQURPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
94GF Score
Get the complete analysis for DHA:SQURPHARMA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:SQURPHARMA has been successfully added to your 
